Core Viewpoint - Haixi New Drug (02637) experienced a significant stock price increase, rising over 7% in early trading and currently up by 5.87%, with a market capitalization exceeding HKD 11 billion [1] Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates research and development, production, and sales capabilities [1] - The company has 15 approved generic drug products covering various therapeutic areas, including the digestive system, cardiovascular system, endocrine system, and nervous system [1] - Haixi New Drug has established a pipeline of four innovative drugs under development, targeting cancer, ophthalmology, and respiratory diseases [1] Market Performance - The current average daily market capitalization of Haixi New Drug is HKD 9.94 billion, which exceeds the threshold requirement for Hong Kong Stock Connect [1]

公开资料显示，海西新药是一家处于商业化阶段的制药公司，集研发、生产及销售能力于一体，具备在 研创新药的管线。截至招股书披露日，海西新药获批上市的仿制药产品有15款，产品组合涵盖了多个治 疗领域，包括消化系统、心血管系统、内分泌系统、神经系统等。公司亦已建立四款在研创新药的产品 管线，涵盖癌症、眼科及呼吸系统疾病。另外，其当前日均流通市值已达99.4亿港元，高于港股通门槛 要求。 海西新药(02637)一度涨超7%，截至发稿，涨6.1%，报140.9港元，成交额1594.55万港元，总市值突破 110亿港元。 ...

智通财经APP获悉，海西新药(02637)一度涨超7%，截至发稿，涨6.1%，报140.9港元，成交额1594.55万 港元，总市值突破110亿港元。 公开资料显示，海西新药是一家处于商业化阶段的制药公司，集研发、生产及销售能力于一体，具备在 研创新药的管线。截至招股书披露日，海西新药获批上市的仿制药产品有15款，产品组合涵盖了多个治 疗领域，包括消化系统、心血管系统、内分泌系统、神经系统等。公司亦已建立四款在研创新药的产品 管线，涵盖癌症、眼科及呼吸系统疾病。另外，其当前日均流通市值已达99.4亿港元，高于港股通门槛 要求。 ...

Group 1 - The company has no specific plans for the separate listing of its subsidiary, Guangsheng Zhonglin Biotechnology Co., Ltd. [1] - The recent capital increase in Guangsheng Zhonglin aims to supplement operational funding and accelerate the research and development of innovative drugs, ultimately enhancing the intrinsic value of Guangsheng Zhonglin [1] - The company commits to timely information disclosure in accordance with regulatory requirements, ensuring that all significant information will be announced through designated media [1]

Core Viewpoint - HaiXi New Drug has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International and CMB International as joint sponsors [1] Group 1: Company Overview - The company employs a "dual-track model" that includes both generic drugs and innovative drugs under development [1] - It has received NMPA approval for 14 generic drugs and has four innovative drugs in development, including a potential first-in-class oncology drug and a potential first oral drug for wAMD/DME/RVO [1] Group 2: Market Focus - The commercial product portfolio primarily targets diseases in the digestive system, cardiovascular system, endocrine system, nervous system, and inflammatory diseases, which collectively account for over 25% of China's total pharmaceutical sales in 2023 [1] - The company's main customers are state-owned pharmaceutical distribution companies, pharmacies, and retailers [1]

Core Viewpoint - Fujian Haixi New Drug Creation Co., Ltd. has submitted its application to the Hong Kong Stock Exchange for listing on the main board, with Huatai International and China Merchants International as joint sponsors. The company is in the commercialization stage and has a diverse product portfolio and pipeline in the rapidly growing therapeutic areas in China [1][2]. Company Overview - Haixi New Drug is a pharmaceutical company that integrates research and development, production, and sales capabilities, with a focus on both generic drugs and innovative drugs in its pipeline [1]. - The company has received approval from the National Medical Products Administration for 14 generic drugs and has established a pipeline of four innovative drugs under development [1]. Product and Market Focus - The company employs a dual-track model, focusing on both generic drugs and innovative drugs. Its generic drugs are characterized by significant technical barriers and market potential, with timely regulatory approvals [1]. - The innovative drug pipeline targets unmet medical needs and has substantial global market potential, including a potential first-in-class oncology drug and an oral drug for treating wAMD/DME/RVO [1]. Financial Performance - As of July 8, 2025, the company's commercialized product portfolio includes generic drugs for digestive, cardiovascular, endocrine, neurological, and inflammatory diseases, which collectively account for over 25% of China's pharmaceutical sales in 2023 [2]. - The company's revenue from the top five customers has shown a decreasing trend from 85.1% in 2022 to 71.7% in the first five months of 2025 [2]. - Revenue figures for the years 2022, 2023, 2024, and the first five months of 2025 are approximately RMB 212 million, RMB 317 million, RMB 467 million, and RMB 249 million, respectively, with corresponding profits of approximately RMB 69 million, RMB 117 million, RMB 136 million, and RMB 90 million [2].

Core Viewpoint - Haixi New Drug has submitted its application to the Hong Kong Stock Exchange for listing, with Huatai International and China Merchants International as joint sponsors, marking a significant step in its growth strategy [1]. Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates research and development, production, and sales, with a pipeline of innovative drugs under development [3]. - The company has a diverse product portfolio in the fastest-growing therapeutic areas in China, having received approval for 14 generic drugs from the National Medical Products Administration [3]. Business Model - The company employs a dual-track model focusing on both generic drugs and innovative drugs in development [3]. - In the generic drug segment, Haixi New Drug has launched a series of products with significant market potential and regulatory approval [3]. Product Pipeline - The innovative drug pipeline targets unmet medical needs with substantial global market potential, including a potential first-in-class oncology drug and an oral medication for treating wAMD/DME/RVO [3]. Financial Performance - Revenue from the top five customers accounted for 85.1%, 73.3%, 72.6%, and 71.7% of total revenue for the years 2022, 2023, 2024, and the five months ending May 31, 2025, respectively [4]. - The company's revenue for the years 2022, 2023, 2024, and the five months ending May 31, 2025, were approximately RMB 212 million, RMB 317 million, RMB 467 million, and RMB 249 million, respectively [4][6]. - The net profit for the same periods was approximately RMB 69 million, RMB 117 million, RMB 136 million, and RMB 90 million, respectively [4][6].

Core Viewpoint - The annual pharmaceutical industry event, CPHI&PMEC China 2025, showcased the comprehensive strength and value advantages of the company's overseas commercialization platform, receiving positive feedback from domestic and international guests [1][2] Group 1: Company Strategy and Development - The company is advancing its "innovation + internationalization" strategy, rapidly progressing in drug research and overseas commercialization, and has established partnerships with several well-known pharmaceutical companies for international collaboration [2] - The company aims to provide superior drugs and comprehensive solutions for global patients by collaborating with outstanding domestic pharmaceutical and medical device enterprises [2] Group 2: Event Highlights - During the CPHI exhibition from June 24 to 26, the company showcased over 20 high-quality drugs, synthetic biology, and medical beauty products, facilitating discussions on its innovative drug pipeline and overseas commercialization with both new and existing clients [2] - The company emphasized its confidence and achievements in overseas business during the forum, highlighting its strategic layout, core advantages in research, production, and sales, as well as its development plans for international markets [2] Group 3: Global Engagement - The company hosted the second "Global Sharing, Co-creating the Future" 2025 International Pharmaceutical High-end Forum, engaging in deep industry dialogue with global clients and partners from 20 countries, including Brazil, Colombia, Saudi Arabia, and Indonesia [2] - The company’s platform for international expansion will continue to be driven by innovation and collaboration, aiming to empower more Chinese pharmaceutical companies to enter international markets [2]